Featured Publications
Real‐world VASCADE closure device versus manual compression use and outcomes in patients with severe common femoral artery disease
Nagpal S, Scierka LE, Castro‐Dominguez Y, Kansal D, Kunnirickal S, Hussain Y, Love K, Aboian E, Smolderen KG, Mena‐Hurtado C. Real‐world VASCADE closure device versus manual compression use and outcomes in patients with severe common femoral artery disease. Catheterization And Cardiovascular Interventions 2022, 100: 776-784. PMID: 36129818, DOI: 10.1002/ccd.30405.Peer-Reviewed Original ResearchMeSH KeywordsAgedFemaleFemoral ArteryHemostatic TechniquesHumansMaleMiddle AgedPuncturesTreatment OutcomeVascular Closure DevicesConceptsPeripheral vascular interventionsManual compressionClosure deviceCommon femoral artery diseaseVascular Quality Initiative databaseFemoral artery diseasePropensity-matched cohortPseudoaneurysm rateRetroperitoneal bleedingArtery diseaseRetrospective reviewMean ageBaseline variablesInstitutional databaseNonsignificant reductionNonsignificant decreaseVascular interventionsMortality ratePatientsCompression useCollagen plugDiseaseInitiative databaseProcedural metricsDevice usePatient-level and external factors in the use of drug-coated balloons and drug-eluting stents in femoropopliteal endovascular interventions
Castro-Dominguez Y, Smolderen KG, Pichert M, Alabi O, Romain G, Huang J, Lee M, Ahmed Z, Peri-Okonny PA, Arham A, Brice A, Chaar CO, Stacy MR, Mena-Hurtado C. Patient-level and external factors in the use of drug-coated balloons and drug-eluting stents in femoropopliteal endovascular interventions. Journal Of Vascular Surgery 2022, 76: 1675-1680. PMID: 35868423, DOI: 10.1016/j.jvs.2022.06.093.Peer-Reviewed Original ResearchConceptsDrug-coated balloonsDrug-eluting stentsBare metal stentsDES useFemoropopliteal endovascular interventionEndovascular interventionMedian odds ratioFemoropopliteal diseaseLesion characteristicsPrimary treatmentChronic kidney disease stage 4Adjusted median odds ratioVascular Quality Initiative registryAppropriate use guidelinesPrior anticoagulant usePatient-level factorsPoor functional statusTrans-Atlantic InterPlain balloon angioplastyPatient-level characteristicsFavorable patency ratesHierarchical logistic regression modelsLogistic regression modelsMeta-analysis publicationsRutherford classificationUse of drug-coated balloons and stents in patients with femoropopliteal artery disease and severe chronic kidney disease
Castro-Dominguez Y, Smolderen K, Romain G, Turner J, Mena-Hurtado C. Use of drug-coated balloons and stents in patients with femoropopliteal artery disease and severe chronic kidney disease. Vascular Medicine 2023, 28: 150-152. PMID: 36710497, DOI: 10.1177/1358863x221148521.Peer-Reviewed Original ResearchThe Vascular Quality Initiative assessment of the Bard Lifestent for the treatment of popliteal artery occlusive disease
Bertges D, Eldrup-Jorgensen J, Eskandari M, Hamdan A, Mena-Hurtado C, Mewissen M, Smith T, Woo E, Cronenwett J, Initiative S. The Vascular Quality Initiative assessment of the Bard Lifestent for the treatment of popliteal artery occlusive disease. Journal Of Vascular Surgery 2023, 78: 1489-1496.e1. PMID: 37648091, DOI: 10.1016/j.jvs.2023.08.122.Peer-Reviewed Original ResearchMeSH KeywordsAgedChronic Limb-Threatening IschemiaFemaleFemoral ArteryHumansLower ExtremityMalePopliteal ArteryProspective StudiesConceptsTarget lesion revascularizationChronic limb-threatening ischemiaTarget vessel revascularizationMajor adverse eventsLimb-threatening ischemiaPopliteal arteryLesion revascularizationMajor amputationVessel revascularizationHemodynamic successSecondary patencyAdverse eventsOcclusive diseaseProcedural successSingle-arm prospective studyProximal popliteal arterySustained clinical successPrimary efficacy outcomePrimary safety outcomeArtery occlusive diseaseComposite primary endpointPrimary-assisted patencyKaplan-Meier analysisSuperficial femoral arteryMajority of stents
2023
Drug‐Coated Balloon and Drug‐Eluting Stent Safety in Patients With Femoropopliteal and Severe Chronic Kidney Disease
Hanna J, Smolderen K, Castro‐Dominguez Y, Romain G, Lee M, Turner J, Mena‐Hurtado C. Drug‐Coated Balloon and Drug‐Eluting Stent Safety in Patients With Femoropopliteal and Severe Chronic Kidney Disease. Journal Of The American Heart Association 2023, 12: e028622. PMID: 36974774, PMCID: PMC10122876, DOI: 10.1161/jaha.122.028622.Peer-Reviewed Original ResearchConceptsEarly-stage chronic kidney diseaseChronic kidney diseaseBare metal stentsDrug-eluting stentsDrug-coated balloonsMortality riskAmputation riskKidney diseaseSevere chronic kidney diseaseMajor amputation riskPlain balloon angioplastyDrug-Coated BalloonAmputation outcomesCKD statusAmputation rateCause mortalityBackground PatientsAdjusted analysisBalloon angioplastyFemoropopliteal interventionsDES useBMS useRegistry dataDisease trialsPatients
2021
Trends in drug-coated device use for peripheral artery disease: Insights from the Vascular Quality Initiative (VQI)
Pichert MD, Smolderen KG, Castro-Dominguez Y, Jelani QU, Nagpal S, Provance JB, Huang J, Malik AO, Secemsky EA, Derbas LA, Mena-Hurtado CI. Trends in drug-coated device use for peripheral artery disease: Insights from the Vascular Quality Initiative (VQI). Vascular Medicine 2021, 27: 73-74. PMID: 34610776, DOI: 10.1177/1358863x211043567.Peer-Reviewed Original Research
2020
Paclitaxel-coated devices in the treatment of femoropopliteal stenosis among patients ≥65 years old: An ACC PVI Registry Analysis
Weissler EH, Annapureddy A, Wang Y, Secemsky EA, Shishehbor MH, Mena-Hurtado C, Jelani QU, Aronow HD, Tsai TT, Patel MR, Curtis JP, Jones WS. Paclitaxel-coated devices in the treatment of femoropopliteal stenosis among patients ≥65 years old: An ACC PVI Registry Analysis. American Heart Journal 2020, 233: 59-67. PMID: 33321119, PMCID: PMC8078180, DOI: 10.1016/j.ahj.2020.12.004.Peer-Reviewed Original ResearchConceptsPeripheral vascular interventionsPCD usePaclitaxel-coated devicesChronic total occlusionSignificant differencesCause mortalityAnalytic cohortFemoropopliteal lesionsOverall cohortPopliteal arteryPrimary outcomeRegistry analysisTotal occlusionUnadjusted ratesFemoropopliteal stenosesInverse probability weightingVascular interventionsAmerican CollegePatientsPractice settingsMortalityReal-world useClaim outcomesDevice useOutcomesSafety and efficacy of paclitaxel drug-coated balloon in femoropopliteal in-stent restenosis
Anantha-Narayanan M, Love K, Nagpal S, Sheikh AB, Regan CJ, Mena-Hurtado C. Safety and efficacy of paclitaxel drug-coated balloon in femoropopliteal in-stent restenosis. Expert Review Of Medical Devices 2020, 17: 533-539. PMID: 32525406, DOI: 10.1080/17434440.2020.1770593.Peer-Reviewed Original ResearchConceptsDrug-coated balloonsPlain old balloon angioplastyPeripheral arterial diseaseFP-ISRFP diseaseStent restenosisEfficacy of DCBUse of DCBPaclitaxel drug-coated balloonFirst-line therapyRecurrence of symptomsSelf-expanding nitinol stentsHigher patency rateLong-term safetyLesion revascularizationEndovascular therapyISR rateRandomized studyArterial diseaseBalloon angioplastyFemoropopliteal segmentPatency ratesCommon siteTerm safetyNitinol stents
2019
Drug‐coated balloon versus plain old balloon angioplasty in femoropopliteal disease: An updated meta‐analysis of randomized controlled trials
Anantha‐Narayanan M, Shah SM, Jelani Q, Garcia S, Ionescu C, Regan C, Mena‐Hurtado C. Drug‐coated balloon versus plain old balloon angioplasty in femoropopliteal disease: An updated meta‐analysis of randomized controlled trials. Catheterization And Cardiovascular Interventions 2019, 94: 139-148. PMID: 30838719, DOI: 10.1002/ccd.28176.Peer-Reviewed Original ResearchMeSH KeywordsAgedAmputation, SurgicalAngioplasty, BalloonCardiovascular AgentsCoated Materials, BiocompatibleEquipment DesignFemaleFemoral ArteryHumansLimb SalvageMalePeripheral Arterial DiseasePopliteal ArteryRandomized Controlled Trials as TopicRisk FactorsTreatment OutcomeVascular Access DevicesVascular PatencyConceptsTarget vessel revascularizationPeripheral arterial diseaseFemoropopliteal diseaseBalloon angioplastyRate of TVRDrug-coated balloon angioplastyPlain old balloon angioplastyAvailable RCT dataDevice-related mortalityImproved vessel patencyPrimary safety endpointMainstay of therapyCochrane's Q statisticLate lumen lossDrug-coated balloonsRandom-effects modelQ statisticMajor amputationSafety endpointVessel revascularizationDCB groupPopliteal arteryArterial diseaseUse of DCBLumen loss
2017
Stellarex Drug-Coated Balloon for Treatment of Femoropopliteal Disease
Krishnan P, Faries P, Niazi K, Jain A, Sachar R, Bachinsky WB, Cardenas J, Werner M, Brodmann M, Mustapha JA, Mena-Hurtado C, Jaff MR, Holden AH, Lyden SP, Mewissen M, Katzen B, Nanjundappa A, Khuddus M, Ricci J, Fry D, Shishehbor M, Bosarge C, Kovach R, Goodwin M, Raja M, Mayeda G, Sandhu J, Rosales O, Crowder W, Paolini D, Henretta J, Desai P, Farhat N, Kang E, Ansel G, Ghani M, Miller W, Pollock C, Korngold E, Angle J, Schultz G, Gensler T, Lopez L, Park J, Al-Khoury G, Joels C, Metzger C. Stellarex Drug-Coated Balloon for Treatment of Femoropopliteal Disease. Circulation 2017, 136: 1102-1113. PMID: 28729250, PMCID: PMC5598919, DOI: 10.1161/circulationaha.117.028893.Peer-Reviewed Original ResearchMeSH KeywordsAgedAngioplasty, BalloonCardiovascular AgentsCoated Materials, BiocompatibleFemaleFemoral ArteryHalf-LifeHumansKaplan-Meier EstimateMaleMiddle AgedPaclitaxelPeripheral Arterial DiseaseProspective StudiesSeverity of Illness IndexSingle-Blind MethodTime FactorsTreatment OutcomeVascular PatencyConceptsDrug-coated balloonsPrimary safety end pointSafety end pointTarget lesion revascularizationLesion revascularizationPrimary patencyEnd pointFemoropopliteal diseaseClinical outcomesPivotal studiesDifferent drug-coated balloonsPrimary effectiveness end pointStellarex drug-coated balloonTarget limb major amputationEffectiveness end pointAnkle-brachial indexProcedure-related deathsFemoropopliteal artery diseasePrimary patency rateDrug-Coated BalloonKaplan-Meier estimatesPaclitaxel plasma concentrationsQuality of lifeDCB cohortMajor amputationManagement of Isolated Atherosclerotic Stenosis of the Common Femoral Artery: A Review of the Literature
Halpin D, Erben Y, Jayasuriya S, Cua B, Jhamnani S, Mena-Hurtado C. Management of Isolated Atherosclerotic Stenosis of the Common Femoral Artery: A Review of the Literature. Vascular And Endovascular Surgery 2017, 51: 220-227. PMID: 28376704, DOI: 10.1177/1538574417702773.Peer-Reviewed Original ResearchConceptsCommon femoral endarterectomyTarget lesion revascularizationCommon femoral arteryCFA stenosisEndovascular therapyEndovascular studiesPrimary patencyAtherosclerotic stenosisTechnical successEndovascular interventionFemoral arteryGood short-term patencyFurther trial dataFirst-line therapyPercentage of patientsCritical limb ischemiaStandard of careNumber of patientsShort-term patencyLower ratesHigh rateEndovascular literatureFemoropopliteal systemLesion revascularizationLimb ischemia
2015
Trial of a Paclitaxel-Coated Balloon for Femoropopliteal Artery Disease
Rosenfield K, Jaff MR, White CJ, Rocha-Singh K, Mena-Hurtado C, Metzger DC, Brodmann M, Pilger E, Zeller T, Krishnan P, Gammon R, Müller-Hülsbeck S, Nehler MR, Benenati JF, Scheinert D. Trial of a Paclitaxel-Coated Balloon for Femoropopliteal Artery Disease. New England Journal Of Medicine 2015, 373: 145-153. PMID: 26106946, DOI: 10.1056/nejmoa1406235.Peer-Reviewed Original ResearchConceptsDrug-coated balloonsPaclitaxel-coated balloonPeripheral artery diseasePercutaneous transluminal angioplastyPrimary patencyArtery diseaseTransluminal angioplastyStandard angioplastyStandard balloonSymptomatic femoropopliteal peripheral artery diseaseFemoropopliteal peripheral artery diseasePrimary efficacy end pointPrimary safety end pointEnd pointSignificant between-group differencesComposite of freedomPrimary safety eventsSymptomatic intermittent claudicationEfficacy end pointSafety end pointFemoropopliteal artery diseaseProportion of patientsSignificant atherosclerotic lesionsBetween-group differencesRate of death
2014
Randomized Controlled Study of Excimer Laser Atherectomy for Treatment of Femoropopliteal In-Stent Restenosis Initial Results From the EXCITE ISR Trial (EXCImer Laser Randomized Controlled Study for Treatment of FemoropopliTEal In-Stent Restenosis)
Dippel EJ, Makam P, Kovach R, George JC, Patlola R, Metzger DC, Mena-Hurtado C, Beasley R, Soukas P, Colon-Hernandez PJ, Stark MA, Walker C, Investigators E. Randomized Controlled Study of Excimer Laser Atherectomy for Treatment of Femoropopliteal In-Stent Restenosis Initial Results From the EXCITE ISR Trial (EXCImer Laser Randomized Controlled Study for Treatment of FemoropopliTEal In-Stent Restenosis). JACC Cardiovascular Interventions 2014, 8: 92-101. PMID: 25499305, DOI: 10.1016/j.jcin.2014.09.009.Peer-Reviewed Original ResearchMeSH KeywordsAgedAlloysAmputation, SurgicalAngioplasty, BalloonAtherectomyChronic DiseaseCombined Modality TherapyConstriction, PathologicFemaleFemoral ArteryHumansLaser TherapyLasers, ExcimerLimb SalvageMaleMiddle AgedPeripheral Arterial DiseasePopliteal ArteryProspective StudiesProsthesis DesignRecurrenceStentsTime FactorsTreatment OutcomeUnited StatesVascular PatencyConceptsPercutaneous transluminal angioplastyTarget lesion revascularizationExcimer laser atherectomyLaser atherectomyAdjunctive percutaneous transluminal angioplastyMajor adverse event rateChronic peripheral artery diseaseLesion lengthLifestyle-limiting claudicationPrimary safety endpointRutherford class 1Target lesion lengthPrimary efficacy endpointMajor adverse eventsPeripheral artery diseaseAdverse event ratesCritical limb ischemiaFemoropopliteal ISRLesion revascularizationEfficacy endpointSafety endpointAdverse eventsLimb ischemiaTransluminal angioplastyArtery disease